- Page 2:
HANDBOOK OFSOPs FOR GOODCLINICAL PR
- Page 10: About PolarisClinical Research Cons
- Page 14: Table of ContentsMON-001.0MON-002.0
- Page 18: Initial SubIRB MemberMinutes Templa
- Page 22: SOP# MON-001.0CompanyEffective Date
- Page 26: CompanyStandard Operating Procedure
- Page 30: SOP# MON-002.0CompanyEffective Date
- Page 34: CompanyStandard Operating Procedure
- Page 38: SOP# MON-003.0CompanyEffective Date
- Page 42: SOP# MON-004.0CompanyEffective Date
- Page 46: SOP# MON-004.0CompanyEffective Date
- Page 50: SOP# MON-005.0CompanyEffective Date
- Page 54: SOP# MON-005.0CompanyEffective Date
- Page 60: SOP# MON-006.0CompanyEffective Date
- Page 64: SOP# MON-006.0CompanyEffective Date
- Page 68: SOP# MON-007.0CompanyEffective Date
- Page 72: SOP# MON-007.0CompanyEffective Date
- Page 76: SOP# MON-007.0CompanyEffective Date
- Page 80: SOP# MON-008.0CompanyEffective Date
- Page 84: SOP# MON-008.0CompanyEffective Date
- Page 88: CompanyStandard Operating Procedure
- Page 92: SOP# MON-009.0CompanyEffective Date
- Page 96: SOP# MON-009.0CompanyEffective Date
- Page 100: SOP# MON-009.0CompanyEffective Date
- Page 104: SOP# MON-009.0CompanyEffective Date
- Page 108:
SOP# MON-009.0CompanyEffective Date
- Page 112:
CompanyStandard Operating Procedure
- Page 116:
SOP# MON-010.0CompanyEffective Date
- Page 120:
SOP# MON-010.0CompanyEffective Date
- Page 124:
SOP# MON-011.0CompanyEffective Date
- Page 128:
SOP# MON-011.02. On-Site Destructio
- Page 132:
SOP# MON-012.0CompanyEffective Date
- Page 136:
SOP# MON-012.0CompanyEffective Date
- Page 140:
SOP# MON-012.0CompanyEffective Date
- Page 144:
SOP# MON-013.0CompanyEffective Date
- Page 148:
SOP# SITE-001.0CompanyEffective Dat
- Page 152:
CompanyStandard Operating Procedure
- Page 156:
SOP# SITE-002.0CompanyEffective Dat
- Page 160:
CompanyStandard Operating Procedure
- Page 164:
CompanyStandard Operating Procedure
- Page 168:
CompanyStandard Operating Procedure
- Page 172:
CompanyStandard Operating Procedure
- Page 176:
SOP# SITE-006.0CompanyEffective Dat
- Page 180:
CompanyStandard Operating Procedure
- Page 184:
SOP# SITE-007.0CompanyEffective Dat
- Page 188:
SOP# SITE-008.0CompanyEffective Dat
- Page 192:
SOP# SITE-008.0CompanyEffective Dat
- Page 196:
SOP# SITE-009.0CompanyEffective Dat
- Page 200:
SOP# SITE-009.0CompanyEffective Dat
- Page 204:
SOP# SITE-009.0CompanyEffective Dat
- Page 208:
SOP# SITE-010.0CompanyEffective Dat
- Page 212:
SOP# SITE-010.0CompanyEffective Dat
- Page 216:
SOP# SITE-011.0CompanyEffective Dat
- Page 220:
SOP# SITE-011.0CompanyEffective Dat
- Page 224:
SOP# SITE-012.0CompanyEffective Dat
- Page 228:
SOP# SITE-013.0CompanyEffective Dat
- Page 232:
SOP# SITE-013.0CompanyEffective Dat
- Page 236:
CompanyStandard Operating Procedure
- Page 240:
SOP# SITE-014.0F. Records Retention
- Page 244:
CompanyStandard Operating Procedure
- Page 248:
SOP# IRB-001.0CompanyEffective Date
- Page 252:
SOP# IRB-002.0CompanyEffective Date
- Page 256:
SOP# IRB-002.0E. IRB SecretaryCompa
- Page 260:
SOP# IRB-002.0CompanyEffective Date
- Page 264:
SOP# IRB-003.0CompanyEffective Date
- Page 268:
SOP# IRB-003.0F. VotingCompanyEffec
- Page 272:
CompanyStandard Operating Procedure
- Page 276:
SOP# IRB-004.0CompanyEffective Date
- Page 280:
SOP# IRB-005.0CompanyEffective Date
- Page 284:
SOP# IRB-005.0CompanyEffective Date
- Page 288:
CompanyStandard Operating Procedure
- Page 292:
SOP# IRB-006.0CompanyEffective Date
- Page 296:
SOP# IRB-006.0CompanyEffective Date
- Page 300:
SOP# IRB-007.0CompanyEffective Date
- Page 304:
CompanyStandard Operating Procedure
- Page 308:
SOP# IRB-008.0CompanyEffective Date
- Page 312:
SOP# IRB-009.0CompanyEffective Date
- Page 316:
SOP# IRB-009.0CompanyEffective Date
- Page 320:
CompanyAdvertisement Review Checkli
- Page 324:
CompanyBiological Samples Inventory
- Page 328:
CompanyData Clarification FormCompo
- Page 332:
CompanyStudy Subject Investigationa
- Page 336:
CompanyInvestigational Drug Shippin
- Page 340:
CompanyDrug Return FormDrug name: S
- Page 344:
CompanyScreening and Enrollment Log
- Page 348:
CompanyInformed ConsentExpedited Re
- Page 352:
CompanySubject Information and Cons
- Page 356:
CompanyStudy Initiation Document Tr
- Page 360:
CompanyInitial Submission FormStudy
- Page 364:
CompanyInitial Submission Form (con
- Page 368:
CompanyInitial Submission Form (con
- Page 372:
CompanyInitial Submission Form (con
- Page 376:
CompanyIRB MEETING MINUTES TEMPLATE
- Page 380:
CompanyAMENDMENTSPrincipal Investig
- Page 384:
CompanyMonitoring LogProtocol #: In
- Page 388:
SubjectnumberSubject Name and Addre
- Page 392:
CompanyIRB Progress Report FormProt
- Page 396:
CompanyStudy Responsibilities FormP
- Page 400:
CompanyReviewer’s ChecklistProtoc
- Page 404:
CompanyIRB Review Results FormPropo
- Page 408:
Code INTENSITY as:1 = Mild2 = Moder
- Page 412:
CompanySerious Adverse Subject Init
- Page 416:
CompanySafety Information FormProto
- Page 420:
CompanyStudy Signature Sheet (contd
- Page 424:
CompanyIRB Notification of Study Te
- Page 428:
CompanyTraining Plan FormEmployee:S
- Page 432:
CompanyEmployeeProject-specific tra
- Page 436:
CompanyStaff Training Request FormE
- Page 440:
CompanySite Evaluation Visit Trip R
- Page 444:
CompanyOverall Assessment (continue
- Page 448:
CompanyMEETING CONTENTINDICATE WHIC
- Page 452:
CompanyPeriodic Site Visit Trip Rep
- Page 456:
CompanySERIOUS ADVERSE EXPERIENCESS
- Page 460:
CompanyStudy Termination Visit Trip
- Page 464:
CompanyStudy Drug (continued)Yes No
- Page 468:
CompanyMeeting with InvestigatorDid